|
Diaceutics PLC - Belfast-based testing laboratories company - Launches daily alerts update for its DXRX Signal platform, which it says will allow clients to identify patients who previously weren’t receiving ‘the most appropriate treatment’ due to lack of timely data. Adds that it has identified over 46,000 patients this year for its biopharma clients. DXRX is a diagnostic commercialisation platform for precision medicine. Chief Executive Officer Peter Keeling said: ‘This data has simply not been accessible previously to pharma, which we believe is one of the reasons such a worryingly high proportion of patients who could benefit from precision medicine are not receiving it in time.’ Current stock price: 107.50 pence, up 1.9% on Tuesday 12-month change: up 17% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
